A groundbreaking “universal” vaccine that could potentially combat various viruses, bacteria, and allergens like dust mites is under development by US scientists. This vaccine, if successful in human trials, may become an annual defense option against seasonal infections, potentially available through the NHS within the next five to seven years.
The new vaccine, created at Stanford University, functions by triggering defensive T cells in the body to combat incoming pathogens. Administered as a nasal spray, it primes T cells in the nasal passages and lungs to be on high alert, significantly reducing the penetration of viruses into the body.
While initial testing in mice has shown promising results, further trials in humans are necessary to evaluate its effectiveness and potential side effects. Researchers are planning clinical trials to assess immune responses by deliberately infecting participants who have received the nasal spray.
Lead researcher Dr. Bali Pulendran envisions this vaccine as a game-changer in medical practice, offering protection against a wide range of respiratory threats like Covid-19, influenza, and common cold viruses, as well as bacterial pneumonia and allergens. However, concerns remain about the potential risks of activating the immune system continuously, which could lead to autoimmune diseases.
Experts, while enthusiastic about the vaccine’s potential, also emphasize the importance of ensuring that boosting the immune system does not inadvertently trigger adverse reactions. The vaccine’s development marks a significant advancement in vaccine technology, with the hope of providing a universal solution to combat various pathogens in the future.
